Reference : Ibandronate in profile: drug characteristics and clinical efficacy.

	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : General & internal medicine
	To cite this reference:	http://hdl.handle.net/2268/20323

Title :	Ibandronate in profile: drug characteristics and clinical efficacy.
Language :	English
Author, co-author :	Reginster, Jean-Yves [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
	Neuprez, Audrey [Université de Liège - ULG > Département des sciences de la santé publique > Epidémiologie et santé publique > >]
	Bruyère, Olivier [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique >]
Publication date :	2008
Journal title :	Expert Opinion on Drug Metabolism & Toxicology
Volume :	4
Issue/season :	7
Pages :	941-51
Peer reviewed :	Yes (verified by ORBi)
Audience :	International
ISSN :	1742-5255
Keywords :	[en] Aged ; Bone Density Conservation Agents/adverse effects/pharmacokinetics/pharmacology/therapeutic use ; Diphosphonates/adverse effects/pharmacokinetics/pharmacology/therapeutic use ; Female ; Humans ; Middle Aged ; Osteoporosis, Postmenopausal/prevention & control
Abstract :	[en] BACKGROUND: Postmenopausal osteoporosis is a serious, chronic condition, for which nitrogen-containing bisphosphonates are now one of the treatments of choice. OBJECTIVE: To review the profile of ibandronate, a monthly oral (150 mg) or quarterly intravenous injection (3 mg) of bisphosphonate. METHODS: The literature search was limited to publications of ibandronate data. RESULTS/CONCLUSION: Ibandronate is rapidly absorbed and distributed in the bone; it is not metabolised and is excreted in urine. Clinical trial data have demonstrated the efficacy of ibandronate in reducing fracture risk, increasing bone mineral density and reducing bone turnover. These data are supported by recent meta-analyses and a large database study that have demonstrated antifracture efficacy with the ibandronate regimens used in clinical practice. Overall, ibandronate has generally been well tolerated. Therefore, ibandronate is a useful treatment for postmenopausal osteoporosis.
Permalink :	http://hdl.handle.net/2268/20323
DOI :	10.1517/17425255.4.7.941

	File(s) associated to this reference
	Fulltext file(s): File Commentary Version Size Access Restricted access Ibandronate in profile - drug characteristics and clinical efficacy_ Expert Opinion 2008_JYR AN OB.pdf Publisher postprint 890.26 kB Request copy

All documents in ORBi are protected by a user license.

 

© ULg Library Network |  Feedback |  ORBi legal notices

Dspace v1.5